- Title
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
- Creator
- Ahmed, Nuzhat; Greening, David; Samardzija, Chantel; Escalona, Ruth; Chen, Maoshan; Findlay, Jock; Kannourakis, George
- Date
- 2016
- Type
- Text; Journal article
- Identifier
- http://researchonline.federation.edu.au/vital/access/HandleResolver/1959.17/102321
- Identifier
- vital:10784
- Identifier
-
https://doi.org/10.1038/srep30061
- Identifier
- ISSN:20452322
- Abstract
- Eighty % of ovarian cancer patients diagnosed at an advanced-stage have complete remission after initial surgery and chemotherapy. However, most patients die within <5 years due to episodes of recurrences resulting from the growth of residual chemoresistant cells. In an effort to identify mechanisms associated with chemoresistance and recurrence, we compared the expression of proteins in ascites-derived tumor cells isolated from advanced-stage ovarian cancer patients obtained at diagnosis (chemonaive, CN) and after chemotherapy treatments (chemoresistant/at recurrence, CR) by using in-depth, high-resolution label-free quantitative proteomic profiling. A total of 2,999 proteins were identified. Using a stringent selection criterion to define only significantly differentially expressed proteins, we report identification of 353 proteins. There were significant differences in proteins encoding for immune surveillance, DNA repair mechanisms, cytoskeleton rearrangement, cell-cell adhesion, cell cycle pathways, cellular transport, and proteins involved with glycine/proline/arginine synthesis in tumor cells isolated from CR relative to CN patients. Pathway analyses revealed enrichment of metabolic pathways, DNA repair mechanisms and energy metabolism pathways in CR tumor cells. In conclusion, this is the first proteomics study to comprehensively analyze ascites-derived tumor cells from CN and CR ovarian cancer patients.
- Publisher
- Nature Publishing Group
- Relation
- Scientific Reports Vol. 6, no. (2016), p. 1-13
- Rights
- Copyright © The Authors. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
- Rights
- Open Access
- Rights
- This metadata is freely available under a CCO license
- Subject
- Ovarian cancer; Residual chemoresistant cells; Preotomics; Ascites-derived tumor cells
- Full Text
- Reviewed
- Hits: 1365
- Visitors: 1527
- Downloads: 196
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Published version | 1 MB | Adobe Acrobat PDF | View Details Download |